| Bioactivity | MYBMIM is an inhibitor for assembly of the molecular MYB:CBP/P300 complex. MYBMIM inhibits growth of leukemia cells[1]. |
| Invitro | MYBMIM (10-20 μM) 通过下调抗凋亡 Bcl2 基因表达来抑制急性髓系白血病细胞的增殖 (6 天) 并诱导细胞凋亡 (apoptosis) (48 h)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> MYBMIM 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | MYBMIM (25 mg/kg，腹膜内注射，每天两次，持续 14 天) 可阻止小鼠异种移植模型中人类白血病肿瘤的进展[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Sequence | Ac-d-{Lys-Leu-Glu-Asn-Glu-Thr-Ser-Met-Leu-Leu-Leu-Glu-Leu-Glu-Lys-Ile-Arg-Lys-Gly-Gly-Arg-Arg-Arg-Gln-Arg-Arg-Lys-Lys-Arg-Gly-Tyr}-NH2 |
| Shortening | Ac-d-{KLENETSMLLLELEKIRKGG-RRRQRRKKRGY}-NH2 |
| Formula | C166H296N60O45S |
| Molar Mass | 3884.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ramaswamy K, et al., Peptidomimetic blockade of MYB in acute myeloid leukemia. Nat Commun. 2018 Jan 9;9(1):110. |